Talimogene laherparepvec (T-VEC) is an oncolytic virus hypothesized to enhance triple-
negative breast cancer (TNBC) responses to neoadjuvant chemotherapy (NAC). This article …

Purpose: Talimogene laherparepvec (TVEC) is an oncolytic herpes simplex 1 virus
approved for treatment of melanoma. We hypothesized intratumoral TVEC may enhance …

Triple-negative breast cancer (TNBC) is a heterogeneous disease comprised of several
biologically distinct subtypes. However, treatment is currently mainly relying on …

Triple-negative breast cancer (TNBC) is the most complex and challenging breast cancer
subtype to treat, and chemotherapy remains the standard of care. Clinically, TNBC has a …

Triple-negative breast cancer (TNBC) is a clinically relevant term referring to breast
carcinomas that do not express the estrogen receptor, progesterone receptor, and human …

551 Background: We have previously shown that neoadjuvant cisplatin has activity in TNBC,
a subtype of breast cancer for which there is no effective targeted therapy. Bevacizumab …

104 Background: Combining immune-checkpoint inhibitors with chemotherapy yielded high
response rates in patients (pts) with metastatic TNBC. Therefore, we evaluated the addition …

591 Background: Both Cb and Bev demonstrate activity when combined with standard
chemotherapy in TNBC. CALGB 40603 is a 2x2 randomized trial that previously …

Background Primary analyses of the phase III BrighTNess trial showed addition of
carboplatin with/without veliparib to neoadjuvant chemotherapy significantly improved …

Breast cancer is not considered anymore a unique disease. Microarray gene expression
analysis led to the identification of 4 major breast cancer “intrinsic” subtypes, including …